|
MechanismPeptidase family A1 inhibitors |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.Japan |
First Approval Date30 Mar 1976 |
/ Not yet recruitingPhase 1 AN OPEN-LABEL, RANDOMIZED, SINGLE DOSE, TWO-STAGE CROSSOVER ADAPTIVE BIOEQUIVALENCE STUDY OF TRIAMCINOLONE ACETONIDE 40 MG/ML STERILE INJECTABLE SUSPENSION (Test product–Lisapharma S.p.A) VERSUS KENACORT® 40 MG/ML SUSPENSION (Reference product – Bristol Myers Squibb) AFTER INTRAMUSCULAR ADMINISTRATION TO HEALTHY VOLUNTEERS
100 Clinical Results associated with Shandong Sito Bio-technology Co., Ltd.
0 Patents (Medical) associated with Shandong Sito Bio-technology Co., Ltd.
100 Deals associated with Shandong Sito Bio-technology Co., Ltd.
100 Translational Medicine associated with Shandong Sito Bio-technology Co., Ltd.